avodart - Urological Sciences Research Foundation
... metabolized by the CYP3A4 isoenzyme to 2 minor mono-hydroxylated metabolites. Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2C19, and CYP2D6 at 2,000 ng/mL (50-fold greater than steady-state serum concentrations). In human serum, following dosing to s ...
... metabolized by the CYP3A4 isoenzyme to 2 minor mono-hydroxylated metabolites. Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2C19, and CYP2D6 at 2,000 ng/mL (50-fold greater than steady-state serum concentrations). In human serum, following dosing to s ...
Product Monograph Template - Standard - GlaxoSmithKline
... • The dosage of ZOVIRAX® (acyclovir) should be reduced in patients with impaired renal function. • Therapy should be initiated as soon as possible after a diagnosis of chickenpox or herpes zoster, or at the first sign or symptoms of an outbreak of genital herpes. • The recommended dose and duration ...
... • The dosage of ZOVIRAX® (acyclovir) should be reduced in patients with impaired renal function. • Therapy should be initiated as soon as possible after a diagnosis of chickenpox or herpes zoster, or at the first sign or symptoms of an outbreak of genital herpes. • The recommended dose and duration ...
Amphetamine-Type Stimulants: A Global Review, 1996
... problem of the future will be associated with what are commonly known as synthetic drugs. The present paper is an attempt to assess the validity of this proposition. The subject is too vast and intricate to cover in a single review, but guidance for achieving a manageable focus can be found in two a ...
... problem of the future will be associated with what are commonly known as synthetic drugs. The present paper is an attempt to assess the validity of this proposition. The subject is too vast and intricate to cover in a single review, but guidance for achieving a manageable focus can be found in two a ...
Intranasal (IN) Medication Administration MBED Clinical Practice
... in the intensive care setting. *Currently looking into its off-label use for procedural sedation in pediatrics when used intranasally. CLINICAL PHARMACOLOGY: Dexmedetomidine is a selective α2-adrenergic receptor agonist that has sedative, analgesic, anesthetic and sympatholytic properties. Its effec ...
... in the intensive care setting. *Currently looking into its off-label use for procedural sedation in pediatrics when used intranasally. CLINICAL PHARMACOLOGY: Dexmedetomidine is a selective α2-adrenergic receptor agonist that has sedative, analgesic, anesthetic and sympatholytic properties. Its effec ...
Acute coronary syndrome secondary to methylphenidate overdose
... potent cardiotoxic compound formed by cocaineethanol metabolic transesterification in humans,11 the clinical significance and toxicity of ethylphenidate are unknown. The presence of ethylphenidate merely indicates co-ingestion with ethanol.10 Because of the similar effects to cocaine and amphetamine ...
... potent cardiotoxic compound formed by cocaineethanol metabolic transesterification in humans,11 the clinical significance and toxicity of ethylphenidate are unknown. The presence of ethylphenidate merely indicates co-ingestion with ethanol.10 Because of the similar effects to cocaine and amphetamine ...
Veterinary Anesthetic and Analgesic Formulary
... anesthetic gas being administered to the animal. In addition, anesthetic duration can be extended for as long as the anesthetic gas is administered. In contrast, injectable anesthetics do not have this flexibility such that once a dose has been administered, it cannot be “removed” to end anesthesi ...
... anesthetic gas being administered to the animal. In addition, anesthetic duration can be extended for as long as the anesthetic gas is administered. In contrast, injectable anesthetics do not have this flexibility such that once a dose has been administered, it cannot be “removed” to end anesthesi ...
What are psychedelics?
... 1938: Albert Hofmann, a chemist working for Sandoz Pharmaceutical, synthesizes LSD25 for the first time in Basel, Switzerland while looking for a blood stimulant. LSD research is not continued until 5 yrs later. Apr 16, 1943: Albert Hofmann accidentally experiences a small amount of LSD for the firs ...
... 1938: Albert Hofmann, a chemist working for Sandoz Pharmaceutical, synthesizes LSD25 for the first time in Basel, Switzerland while looking for a blood stimulant. LSD research is not continued until 5 yrs later. Apr 16, 1943: Albert Hofmann accidentally experiences a small amount of LSD for the firs ...
Efficacy of Propofol and Midazolam in conscious sedation for
... Propofol25,7when administered as bolus injections which increase the potential for both over sedation or under sedation. Our sedation technique involved titrating intravenous midazolam to an ideal sedation end point according to patients response in order to avoid over sedation or under sedation. Ta ...
... Propofol25,7when administered as bolus injections which increase the potential for both over sedation or under sedation. Our sedation technique involved titrating intravenous midazolam to an ideal sedation end point according to patients response in order to avoid over sedation or under sedation. Ta ...
Transungual Drug Delivery: An Overview
... Physical, chemical and mechanical methods have been used to decrease the nail barrier. Within each of these broad categories, many techniques exist to enhance penetration. Mechanical modes of penetration enhancement are typically straightforward, and have the most in vivo experience associated with ...
... Physical, chemical and mechanical methods have been used to decrease the nail barrier. Within each of these broad categories, many techniques exist to enhance penetration. Mechanical modes of penetration enhancement are typically straightforward, and have the most in vivo experience associated with ...
pi_azactam_injection - Products - Bristol
... Average urine concentrations of aztreonam were approximately 1100 mcg/mL, 3500 mcg/mL, and 6600 mcg/mL within the first 2 hours following single 500 mg, 1 g, and 2 g intravenous doses of AZACTAM (30-minute infusions), respectively. The range of average concentrations for aztreonam in the 8- to 12-ho ...
... Average urine concentrations of aztreonam were approximately 1100 mcg/mL, 3500 mcg/mL, and 6600 mcg/mL within the first 2 hours following single 500 mg, 1 g, and 2 g intravenous doses of AZACTAM (30-minute infusions), respectively. The range of average concentrations for aztreonam in the 8- to 12-ho ...
Astaxanthin - Pure Encapsulations
... Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. ...
... Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. ...
LMX4 SmPC SOP FPL21 Appendix version-3
... should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine including acutely ill, debilitated, or elderly patients. Lidocaine coming in contact with the eye should be avoided because animal studies have demonstrated severe eye irritation. Also the loss of ...
... should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine including acutely ill, debilitated, or elderly patients. Lidocaine coming in contact with the eye should be avoided because animal studies have demonstrated severe eye irritation. Also the loss of ...
Product Monograph CEFTIN
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents including CEFTIN® (see ADVERSE REACTIONS). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symp ...
... Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents including CEFTIN® (see ADVERSE REACTIONS). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symp ...
Antiplatelet Drugs - OSU Center for Continuing Medical Education
... 5HT ⫽ 5 hydroxytryptamine; vWF ⫽ von Willebrand factor; 5⬘AMP ⫽ 5⬘ adenosine monophosphate; PAF ⫽ platelet aggregating factor; GP ⫽ glycoprotein; P ⫽ purinergic. (From Gladding et al.,33 with permission.) ...
... 5HT ⫽ 5 hydroxytryptamine; vWF ⫽ von Willebrand factor; 5⬘AMP ⫽ 5⬘ adenosine monophosphate; PAF ⫽ platelet aggregating factor; GP ⫽ glycoprotein; P ⫽ purinergic. (From Gladding et al.,33 with permission.) ...
IMPURITIES IN PHARMACEUTICALS
... The specifications for a new substance should include limits for impurities. Stability studies, chemical development studies, and routine batch analyses can be used to predict those impurities likely to occur in the commercial product. The selection of impurities to include in the new substance spec ...
... The specifications for a new substance should include limits for impurities. Stability studies, chemical development studies, and routine batch analyses can be used to predict those impurities likely to occur in the commercial product. The selection of impurities to include in the new substance spec ...
Clinician`s Resource Paper
... gastric epithelium. Elevated gastric Zn concentration is maintained for a significantly longer period of time after Zinc-L-Carnosine compared to zinc sulfate administration (Figure 1). Peak plasma Zn ...
... gastric epithelium. Elevated gastric Zn concentration is maintained for a significantly longer period of time after Zinc-L-Carnosine compared to zinc sulfate administration (Figure 1). Peak plasma Zn ...
Hydromorphone Hydrochloride Injection, USP, CII (1 mg/mL)
... the patient's degree of opioid tolerance; the daily dose, potency, and specific characteristics of the opioid the patient has been taking ...
... the patient's degree of opioid tolerance; the daily dose, potency, and specific characteristics of the opioid the patient has been taking ...
![Synthesis of Clinical-Grade [18F]-Fluoroestradiol as a Surrogate](http://s1.studyres.com/store/data/013425922_1-240afe5809811a7eaa5494714686588a-300x300.png)
November 2015 – Positive Recommendations (Word 80KB)
... The PBAC recommended the listing of atazanavir/cobicistat on a costminimisation basis with atazanavir plus ritonavir provided concomitantly. The equi-effective doses are atazanavir 300 mg (one capsule) plus cobicistat 150 mg (one tablet) once daily over 48 weeks is equal to atazanavir 300 mg (one ca ...
... The PBAC recommended the listing of atazanavir/cobicistat on a costminimisation basis with atazanavir plus ritonavir provided concomitantly. The equi-effective doses are atazanavir 300 mg (one capsule) plus cobicistat 150 mg (one tablet) once daily over 48 weeks is equal to atazanavir 300 mg (one ca ...
Cephalosporins
... has had a reaction to penicillin is also at risk for a reaction to cephalosporins. B. Pharmacokinetics Many cephalosporins are administered parenterally because they aren’t absorbed from the GI tract. Some cephalosporins are absorbed from the GI tract and can be administered orally, but food usually ...
... has had a reaction to penicillin is also at risk for a reaction to cephalosporins. B. Pharmacokinetics Many cephalosporins are administered parenterally because they aren’t absorbed from the GI tract. Some cephalosporins are absorbed from the GI tract and can be administered orally, but food usually ...
The Use of Midazolam in Paediatric Dentistry: A Review of the
... over-sedation, respiratory depression or paradoxical reactions caused by benzodiazepines. No paediatric dose has been recommended by manufacturer and it is not licensed for use in children. Adult dose is 200 micrograms given over 15 seconds and further 100 microgram doses at 60 second intervals if r ...
... over-sedation, respiratory depression or paradoxical reactions caused by benzodiazepines. No paediatric dose has been recommended by manufacturer and it is not licensed for use in children. Adult dose is 200 micrograms given over 15 seconds and further 100 microgram doses at 60 second intervals if r ...
Lucrin® PDs Depot 3.75 mg
... breast cancer over 12 weeks. Mean leuprorelin acetate levels were above 0.1 ng/mL after four weeks and remained stable after re-injection (at 8 and 12 weeks). There was no tendency for drug accumulation. Distribution The mean steady-state volume of distribution of leuprorelin following intravenous b ...
... breast cancer over 12 weeks. Mean leuprorelin acetate levels were above 0.1 ng/mL after four weeks and remained stable after re-injection (at 8 and 12 weeks). There was no tendency for drug accumulation. Distribution The mean steady-state volume of distribution of leuprorelin following intravenous b ...
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
... important role in health and disease by modulating gene expression, and 4) siRNAs- these 18–25 nucleotide long duplexes are potent activators of the innate immune system that have been shown to initiate sequence-specific post-transcriptional gene silencing. Although all of these strategies can poten ...
... important role in health and disease by modulating gene expression, and 4) siRNAs- these 18–25 nucleotide long duplexes are potent activators of the innate immune system that have been shown to initiate sequence-specific post-transcriptional gene silencing. Although all of these strategies can poten ...
Pharmacokinetics
Pharmacokinetics, sometimes abbreviated as PK (from Ancient Greek pharmakon ""drug"" and kinetikos ""moving, putting in motion""; see chemical kinetics), is a branch of pharmacology dedicated to determining the fate of substances administered externally to a living organism. The substances of interest include pharmaceutical agents, hormones, nutrients, and toxins. It attempts to discover the fate of a drug from the moment that it is administered up to the point at which it is completely eliminated from the body.Pharmacokinetics describes how the body affects a specific drug after administration through the mechanisms of absorption and distribution, as well as the chemical changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug. Pharmacokinetic properties of drugs may be affected by elements such as the site of administration and the dose of administered drug. These may affect the absorption rate. Pharmacokinetics is often studied in conjunction with pharmacodynamics, the study of a drug's pharmacological effect on the body.A number of different models have been developed in order to simplify conceptualization of the many processes that take place in the interaction between an organism and a drug. One of these models, the multi-compartment model, gives the best approximation to reality; however, the complexity involved in using this type of model means that monocompartmental models and above all two compartmental models are the most-frequently used. The various compartments that the model is divided into are commonly referred to as the ADME scheme (also referred to as LADME if liberation is included as a separate step from absorption): Liberation - the process of release of a drug from the pharmaceutical formulation. See also IVIVC. Absorption - the process of a substance entering the blood circulation. Distribution - the dispersion or dissemination of substances throughout the fluids and tissues of the body. Metabolization (or biotransformation, or inactivation) – the recognition by the organism that a foreign substance is present and the irreversible transformation of parent compounds into daughter metabolites. Excretion - the removal of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.The two phases of metabolism and excretion can also be grouped together under the title elimination.The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug.All these concepts can be represented through mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics. Such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism.The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine.